Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
DaVita Inc. (DVA) Insider Trading Activity
Healthcare • Medical Care Facilities • 70,000 employees
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Total Value
-$147,891,746.68
Total Shares
-911,460
Average Trade Value
-$4,621,617.08
Most Active Insider
Berkshire Hathaway Inc
Total Activity: $147,740,046
Largest Single Transaction
$31,684,430
by Berkshire Hathaway Inc on Feb 11, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Feb 19, 2025 | 65,482 | $10,058,363 | 35,206,935 (-0.2%) | Sale | ||
| Feb 19, 2025 | 9,477 | $1,471,273 | 35,142,479 (-0.0%) | Sale | ||
| Feb 19, 2025 | 54,979 | $8,492,881 | 35,151,956 (-0.2%) | Sale | ||
| Feb 18, 2025 | 28,515 | $4,431,394 | 35,274,417 (-0.1%) | Sale | ||
| Feb 18, 2025 | 39,531 | $6,075,369 | 35,352,948 (-0.1%) | Sale | ||
| Feb 18, 2025 | 50,016 | $7,738,701 | 35,302,932 (-0.1%) | Sale | ||
| Feb 18, 2025 | 1,800 | $284,418 | 35,272,417 (-0.0%) | Sale | ||
| Feb 18, 2025 | 200 | $31,222 | 35,274,217 (-0.0%) | Sale | ||
| Feb 14, 2025 | 30,075 | $4,559,337 | 35,828,272 (-0.1%) | Sale | ||
| Feb 14, 2025 | 34,132 | $5,146,420 | 35,858,347 (-0.1%) | Sale | ||
| Feb 14, 2025 | 34,789 | $5,312,385 | 35,793,483 (-0.1%) | Sale | ||
| Feb 14, 2025 | 77,665 | $11,934,113 | 35,715,818 (-0.2%) | Sale | ||
| Feb 14, 2025 | 66,208 | $10,373,635 | 35,487,163 (-0.2%) | Sale | ||
| Feb 14, 2025 | 65,483 | $10,329,374 | 35,421,680 (-0.2%) | Sale | ||
| Feb 14, 2025 | 91,987 | $14,230,766 | 35,623,831 (-0.3%) | Sale | ||
| Feb 14, 2025 | 70,460 | $10,959,229 | 35,553,371 (-0.2%) | Sale | ||
| Feb 14, 2025 | 27,901 | $4,419,834 | 35,393,779 (-0.1%) | Sale | ||
| Feb 14, 2025 | 1,300 | $206,906 | 35,392,479 (-0.0%) | Sale | ||
| Feb 11, 2025 | 203,091 | $31,684,430 | 35,892,479 (-0.6%) | Sale | ||
|
Chief Legal Pub. Affairs Off
Officer
|
Nov 27, 2024 | 8,078 | $879,937 | 97,706 (+8.3%) | Exercise/Conversion | |
|
Chief Legal Pub. Affairs Off
Officer
|
Nov 27, 2024 | 1,439 | $241,694 | 91,028 (-1.6%) | Payment of Exercise Price | |
|
Chief Legal Pub. Affairs Off
Officer
|
Nov 27, 2024 | 5,239 | $879,942 | 92,467 (-5.7%) | Sale to Issuer | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 5,754 (+5.4%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 1,828 (+17.1%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 312 (+100.0%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 24,886 (+1.3%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 3,633 (+8.6%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 4,546 (+6.9%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 612 (+51.0%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 16,004 (+1.9%) | Grant | |
|
Chief Executive Officer
Director, Officer
|
Nov 15, 2024 | 37,423 | $0 | 875,258 (+4.3%) | Grant | |
|
Director
|
Nov 15, 2024 | 312 | $10,000 | 19,285 (+1.6%) | Grant |